Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 6/20 | 0.45 |
| ▸ | GIPR | P48546 | 6/20 | 0.45 |
| ▸ | GLP1R | P43220 | 4/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.38 |
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643553 | 0.84 | GCGR (0.40) | GCGRGIPRGLP1RMCHR1CNR1 | |
| SCHEMBL2644428 | 0.83 | GCGR (0.39) | GCGRGIPRCXCR3ALDH1A1 | |
| SCHEMBL2652200 | 0.82 | GCGR (0.67) | GCGRGIPRGLP1RMCHR1ALDH1A1 | |
| SCHEMBL2647066 | 0.81 | GCGR (0.48) | GCGRGIPRGLP1RMCHR1CNR1 | |
| SCHEMBL2643524 | 0.80 | GCGR (0.70) | GCGRGIPRGLP1RMCHR1 | |
| SCHEMBL2643526 | 0.80 | GCGR (0.70) | GCGRGIPRGLP1RMCHR1 | |
| SCHEMBL2643360 | 0.80 | CNR1 (0.41) | GCGRCNR1MAPT | |
| SCHEMBL2643365 | 0.77 | GCGR (0.49) | GCGRGIPRGLP1RMCHR1CNR1 | |
| SCHEMBL2651577 | 0.76 | GCGR (0.69) | GCGRGIPRGLP1RMCHR1 | |
| SCHEMBL2654184 | 0.76 | GCGR (0.69) | GCGRGIPRGLP1RMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116483-A1 | Glucagon antagonists/inverse agonists | BEHRENS CARSTEN (DK) | 2004-06-17 | — | — | US | disclosed |
| US-6649641-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.